Avid Radiopharmaceuticals
Marcy Williams has extensive work experience in the healthcare industry. Marcy currently holds the position of Sr. Director, Clinical Imaging Operations at Avid Radiopharmaceuticals since December 2022. Prior to this, they worked at Eli Lilly and Company, where they held several roles, including Associate Director of Diabetes Global Medical Affairs Project Management and Associate Director of Clinical Laboratory Operations, Oncology. In these roles, they were responsible for managing teams, developing and implementing plans, and overseeing vendor relationships. Before joining Eli Lilly and Company, Marcy worked at Indiana University School of Medicine, where they served as the Director of Radiation Oncology/IU Cyclotron Operations and also held the position of Certified Medical Dosimetrist. Their responsibilities included operational and financial oversight, treatment planning for cancer patients, and academic leadership. Marcy also has experience working as a Radiation Therapist at various medical centers.
Marcy Williams has a degree in Radiation Therapy (B.S. RT(T)) from Indiana University Bloomington. Marcy also has an MBA/HCM (Master of Business Administration in Healthcare Management) from the University of Phoenix. No specific start or end years for both degrees are provided.
This person is not in any offices
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.